- Global Pharma News & Resources

Global Hyperlipidemia Drugs Market Overview 2020, Demand by Regions, Types and Analysis of Key Players

According to the latest report by IMARC Group, titled, “Hyperlipidemia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025", the global hyperlipidemia drugs market grew at a CAGR of around 3% during 2014-2019.

Hyperlipidemia refers to a health condition where an excessive quantity of lipids, such as cholesterol and triglycerides, is produced into the blood. This condition may lead to cardiac stroke, peripheral vascular disorders, atherosclerosis, diabetes, obesity, hypertension, and various cardiovascular diseases. Some of the hyperlipidemia drugs include statins, bile acid sequestrants, cholesterol absorption inhibitors, PCSK9 inhibitors, fibric acid derivatives, etc. These drugs help in reducing cholesterol production levels in the liver along with lowering the quantity of lipids from the bloodstream.

Get a PDF Sample for more detailed market insights:

Market Trends

The rising prevalence of numerous lifestyle disorders, such as hypertension, obesity, cardiovascular diseases, etc., due to sedentary consumer lifestyles, is driving the demand for hyperlipidemia drugs. Furthermore, the increasing geriatric population who are more prone to the risk of high cholesterol and cardiovascular diseases, is also augmenting the market growth. Additionally, the development of novel drug classes with improved endothelial function and stable atherosclerotic plaques is further propelling the demand for hyperlipidemia drugs. Besides this, the reduction in the prices of PCSK9 inhibitors, such as Repatha and Praluent, is expected to replace several expensive therapies, thereby catalyzing the global market for hyperlipidemia drugs.

Insights on Market Segmentation:

Breakup by Drug Type:

Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
PCSK9 Inhibitors
Fibric Acid Derivatives

Breakup by End User:


For more information about this report visit:

Breakup by Region:

North America
Asia Pacific
Latin America
Middle East and Africa

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of the key players being Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc. and Sanofi S.A.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us

30 N Gould St
Ste R
Sheridan, WY 82801
Follow us on twitter: @imarcglobal

Global Hyperlipidemia Drugs Market Overview 2020, Demand by Regions, Types and Analysis of Key Players

Editor Details

Last Updated: 29-Sep-2020